Lushang Freda PharmaceuticalLtd Past Earnings Performance
Past criteria checks 4/6
Lushang Freda PharmaceuticalLtd's earnings have been declining at an average annual rate of -22.5%, while the Real Estate industry saw earnings declining at 10.6% annually. Revenues have been declining at an average rate of 12% per year. Lushang Freda PharmaceuticalLtd's return on equity is 5.8%, and it has net margins of 5.9%.
Key information
-22.5%
Earnings growth rate
-22.7%
EPS growth rate
| Real Estate Industry Growth | -5.2% |
| Revenue growth rate | -12.0% |
| Return on equity | 5.8% |
| Net Margin | 5.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lushang Freda PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,986 | 237 | 1,593 | 157 |
| 30 Jun 24 | 4,031 | 240 | 1,643 | 154 |
| 31 Mar 24 | 4,197 | 233 | 1,686 | 156 |
| 31 Dec 23 | 4,579 | 303 | 1,704 | 153 |
| 30 Sep 23 | 7,817 | 130 | 1,741 | 155 |
| 30 Jun 23 | 10,590 | 47 | 1,711 | 144 |
| 31 Mar 23 | 12,741 | 108 | 1,685 | 141 |
| 31 Dec 22 | 12,951 | 45 | 1,677 | 134 |
| 30 Sep 22 | 14,543 | 13 | 1,750 | 117 |
| 30 Jun 22 | 13,131 | 240 | 1,788 | 123 |
| 31 Mar 22 | 12,140 | 342 | 1,708 | 118 |
| 31 Dec 21 | 12,363 | 362 | 1,638 | 119 |
| 30 Sep 21 | 12,929 | 729 | 1,568 | 111 |
| 30 Jun 21 | 14,137 | 710 | 1,431 | 100 |
| 31 Mar 21 | 13,915 | 662 | 1,307 | 88 |
| 31 Dec 20 | 13,615 | 639 | 1,169 | 77 |
| 30 Sep 20 | 10,316 | 572 | 1,029 | 68 |
| 30 Jun 20 | 9,817 | 482 | 986 | 62 |
| 31 Mar 20 | 10,307 | 364 | 980 | 53 |
| 31 Dec 19 | 10,289 | 345 | 1,033 | 46 |
| 30 Sep 19 | 10,373 | 222 | 979 | 32 |
| 30 Jun 19 | 10,159 | 195 | 949 | 30 |
| 31 Mar 19 | 9,261 | 184 | 875 | 30 |
| 31 Dec 18 | 8,821 | 162 | 823 | 30 |
| 30 Sep 18 | 10,105 | 166 | 1,093 | 47 |
| 30 Jun 18 | 8,694 | 159 | 961 | 37 |
| 31 Mar 18 | 8,476 | 129 | 868 | 30 |
| 31 Dec 17 | 8,287 | 128 | 753 | 24 |
| 30 Sep 17 | 7,576 | 102 | 296 | 0 |
| 30 Jun 17 | 7,909 | 98 | 306 | 0 |
| 31 Mar 17 | 7,370 | 94 | 308 | 0 |
| 31 Dec 16 | 7,646 | 92 | 316 | 0 |
| 30 Sep 16 | 7,151 | 107 | 337 | 0 |
| 30 Jun 16 | 5,870 | 101 | 329 | 0 |
| 31 Mar 16 | 6,118 | 103 | 332 | 0 |
| 31 Dec 15 | 5,864 | 112 | 324 | 0 |
| 30 Sep 15 | 5,109 | 166 | 336 | 0 |
| 30 Jun 15 | 6,365 | 205 | 325 | 0 |
| 31 Mar 15 | 5,908 | 207 | 330 | 0 |
| 31 Dec 14 | 5,682 | 206 | 334 | 0 |
| 30 Sep 14 | 6,387 | 287 | 344 | 0 |
| 30 Jun 14 | 5,790 | 273 | 372 | 0 |
| 31 Mar 14 | 5,477 | 272 | 353 | 0 |
| 31 Dec 13 | 5,293 | 263 | 344 | 0 |
Quality Earnings: 600223 has high quality earnings.
Growing Profit Margin: 600223's current net profit margins (5.9%) are higher than last year (1.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600223's earnings have declined by 22.5% per year over the past 5 years.
Accelerating Growth: 600223's earnings growth over the past year (82.3%) exceeds its 5-year average (-22.5% per year).
Earnings vs Industry: 600223 earnings growth over the past year (82.3%) exceeded the Real Estate industry -38.4%.
Return on Equity
High ROE: 600223's Return on Equity (5.8%) is considered low.